medigraphic.com
ISSN 2007-6800 (Print)

2016, Number 3

<< Back Next >>

Rev Mex Traspl 2016; 5 (3)

Infections in kidney transplant patients at Centro Médico Nacional de Occidente

Ramírez-Zermeño AE, Marcial-Guzmán M, Torres-González MA, Cerrillos-Gutiérrez JI, Rojas-Campos E, Gómez-Navarro B

Language: Spanish
References: 41
Page: 102-112
PDF size: 286.33 Kb.


ABSTRACT

Introduction: The patients after renal transplant infections continue to be an important cause of morbidity and mortality in this patient population. It is very important to focus on prevention, through a meticulous review of its Protocol pre-transplant and back to the same narrow track. Infections remain a presentation consistent with time post-transplant scheme, so the model timeline of infections developed by Dr. Fishman, far offers a basic tool to identify major risk factors based on the time in which the patient is located as well as the main factors of risk in each of them. Based on the above, we have three periods: those early infections that occur in the first four weeks, second period from the 1st to the sixth month and third period to 6 months. It is important to emphasize that some indifferent to time post variables are episodes of rejection, therapy anti-rejection, neutropenia and co-infection with Cytomegalovirus, Epstein-Barr and herpes virus. Material and methods: The aim of this study was to describe the frequency and risk factors of infections and major clinical syndromes associated with infection in renal transplant patients of Hospital specialties Center doctor national of the West, in one year post-transplant follow-up. The study was a retrospective cohort, from 1 January to 31 December 2015 in specialties Hospital, national medical center of Occidente, Guadalajara, Jalisco, Mexico. Results: A total of 1409 there were revenue in the service of Nephrology and transplant of the Hospital specialties Center doctor national of the West, of which 325 were infectious processes represent 23% of income by infections during from January 1 to December 31, 2015. Demographic characteristics the average age was 31.5 in ± 10.8, 63% men, 37% women, 56% transplant from live donor related, 32 of brain death, in 44% of cases is induced with basiliximab, 34% with timoglobulina and 14% timoglobulina + immunoglobulin. Previous events of rejection of which 11% reject cellular and humoral 1%, of these patients, 12% received anti-rejection treatment had occurred in 15% of patients. Presentation of post-transplant infections median was 4 months, with a wide range of presentation between 2-11.5 months. Urinary tract infections were the most frequent infection in our cohort, representing 54%, followed by 4%, 3%, 2.5 pneumonia CMV parvovirus, 2% % Polyomavirus, 2% invasive mycoses, 0.6% tuberculosis. Conclusions: A multivariate logistic regression analysis was performed to try to establish the main factors of risk and predict the risk of infections.


REFERENCES

  1. Karuthu S, Blumberg EA. Common infections in kidney transplant recipients. Clin J Am Soc Nephrol. 2012; 7 (12): 2058-2070.

  2. Fishman JA. From the classic concepts to modern practice. Clin Microbiol Infect. 2014; 20 Suppl. 7: 4-9.

  3. Ko KS, Cho DO, Ahn JH, Lee TW, Ihm CG, Chang SG et al. Infections after renal transplantation. Transplant Proc. 1994; 26 (4): 2072-2074.

  4. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007; 357 (25): 2601-2614.

  5. Fischer SA, Avery RK. AST Infectious Disease Community of Practice: screening of donor and recipient prior to solid organ transplantation. Am J Transplant. 2009 Suppl. 4: S7-S18.

  6. Sia IG, Paya CV. Infectious complications following renal transplantation. Surg Clin North Am. 1998; 78 (1): 95-112.

  7. Morris MI, Fischer SA, Ison MG. Infections transmitted by transplantation. Infect Dis Clin North Am. 2010; 24 (2): 497-514.

  8. Wilck M, Fishman JA. The challenges of infection in transplantation: donador-derived infections. Curr Opin Transplan. 2005; 10: 301-306.

  9. Keven K, Basu A, Re L, Tan H, Marcos A, Fung JJ et al. Clostridium difficile colitis in patients after kidney and pancreas-kidney transplantation. Transpl Infect Dis. 2004; 6 (1): 10-14.

  10. Hadley S, Karchmer AW. Fungal infections in solid organ transplant recipients. Infect Dis Clin North Am. 1995; 9 (4): 1045-1074.

  11. Castón JJ, López-Oliva MO, Torre-Cisneros J, Del Castillo D. Infecciones en el trasplante renal. Nefrología. 2012; 7: 0. doi: 10.3265/Nefrologia.2010.pub1.ed80.chapter2836

  12. Giessing M. Urinary tract infection in renal transplantation. Arab J Urol. 2012; 10 (2): 162-168.

  13. Ariza-Heredia EJ, Beam EN, Lesnick TG, Kremers WK, Cosio FG, Razonable RR. Urinary tract infections in kidney transplant recipients: role of gender, urologic abnormalities, and antimicrobial prophylaxis. Ann Transplant. 2013; 18: 195-204.

  14. Parasuraman R, Julian K; AST Infectious Diseases Community of Practice. Urinary tract infections in solid organ transplantation. Am J Transplant. 2013; 13 Suppl 4: 327-336.

  15. Castañeda DA, León K, Martín R, López L, Pérez H, Lozano E. Urinary tract infection and kidney transplantation: a review of diagnosis, causes, and current clinical approach. Transplant Proc. 2013; 45 (4): 1590-1592.

  16. Lim JH, Cho JH, Lee JH, Park YJ, Jin S, Park GY et al. Risk factors for recurrent urinary tract infection in kidney transplant recipients. Transplant Proc. 2013; 45 (4): 1584-1589.

  17. Rizvi SJ, Chauhan R, Gupta R, Modi P. Significance of pretransplant urinary tract infection in short-term renal allograft function and survival. Transplant Proc. 2008; 40 (4): 1117-1118.

  18. de Souza RM, Olsburgh J. Urinary tract infection in the renal transplant patient. Nat Clin Pract Nephrol. 2008; 4 (5): 252-264.

  19. Aguado JM, Torre-Cisneros J, Fortún J, Benito N, Meije Y, Doblas A et al. Documento de consenso para el tratamiento de la tuberculosis en pacientes con trasplante de órgano sólido. Enferm Infecc Microbiol Clin. 2009; 27 (8): 465-473.

  20. Muñoz P, Rodríguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis. 2005; 40 (4): 581-587.

  21. Torre-Cisneros J, Castón JJ, Moreno J, Rivero A, Vidal E, Jurado R et al. Tuberculosis in the transplant candidate: importance of early diagnosis and treatment. Transplantation. 2004; 77 (9): 1376-1380.

  22. Martin SI, Fishman JA; AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant. 2009; 9 Suppl 4: S227-S233.

  23. Singh N. Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy. Clin Infect Dis. 2000; 31 (2): 545-553.

  24. Abbott KC, Hypolite I, Poropatich RK, Hshieh P, Cruess D, Hawkes CA et al. Hospitalizations for fungal infections after renal transplantation in the United States. Transpl Infect Dis. 2001; 3 (4): 203-211.

  25. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev. 1997; 10 (1): 86-124.

  26. Tolkoff-Rubin NE, Rubin RH. Opportunistic fungal and bacterial infection in the renal transplant recipient. J Am Soc Nephrol. 1992; 2 (12 Suppl): S264-S269.

  27. Castón-Osorio JJ, Zurbano-Goñi F. Efectos indirectos de la infección por citomegalovirus. Enferm Infecc Microbiol Clin. 2011; 29 Suppl 6: 6-10.

  28. Morales-Buenrostro LE, Alberú GJ. Infecciones en el receptor de trasplante renal. Capítulo: Citomegalovirus en receptores de trasplante renal. Publicaciones Permanyer; 2012. pp. 87-95.

  29. Helanterä I, Schachtner T, Hinrichs C, Salmela K, Kyllönen L, Koskinen P et al. Current characteristics and outcome of cytomegalovirus infections after kidney transplantation. Transpl Infect Dis. 2014; 16 (4): 568-577.

  30. Viot B, Garrigue I, Taton B, Bachelet T, Moreau JF, Dechanet-Merville J et al. Two-year post-transplantation cytomegalovirus DNAemia in asymptomatic kidney transplant recipients: incidence, risk factors, and outcome. Transpl Infect Dis. 2015; 17 (4): 497-509.

  31. Song AT, Abdala E, Bonazzi PR, Bacchella T, Machado MC. Does mycophenolate mofetil increase the risk of cytomegalovirus infection in solid organ transplant recipients?--A mini-review. Braz J Infect Dis. 2006; 10 (2): 132-138.

  32. Hirsch HH, Randhawa P; AST Infectious Diseases Community of Practice. BK virus in solid organ transplant recipients. Am J Transplant. 2009; 9 Suppl 4: S136-S146.

  33. J Thamboo TP, Jeffery KJ, Friend PJ, Turner GD, Roberts IS. Urine cytology screening for polyoma virus infection following renal transplantation: the Oxford experience. Clin Pathol. 2007; 60 (8): 927-930.

  34. Hariharan S. BK virus nephritis after renal transplantation. Kidney Int. 2006; 69 (4): 655-662.

  35. Eid AJ, Posfay-Barbe KM; AST Infectious Diseases Community of Practice. Parvovirus B19 in solid organ transplant recipients. Am J Transplant. 2009; 9 Suppl 4: S147-S150.

  36. Cortázar-Benítez LF, González-Patiño MA, Barbosa-Zamora A, Pardinas-Llergo MJ, Rodríguez-Weber FL, Díaz-Greene EJ. Infecciones tempranas postrasplante renal. Med Int Méx. 2015; 31 (5): 559-566.

  37. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ. 2005; 331 (7520): 810.

  38. Singh N. Infectious complications in organ transplant recipients with the use of calcineurin-inhibitor agent-based immunosuppressive regimens. Curr Opin Infect Dis. 2005; 18 (4): 342-345.

  39. Veroux M, Giuffrida G, Corona D, Gagliano M, Scriffignano V, Vizcarra D et al. Infective complications in renal allograft recipients: epidemiology and outcome. Transplant Proc. 2008; 40 (6): 1873-1876.

  40. Silva M Jr, Marra AR, Pereira CA, Medina-Pestana JO, Camargo LF. Bloodstream infection after kidney transplantation: epidemiology, microbiology, associated risk factors, and outcome. Transplantation. 2010; 90 (5): 581-587.

  41. Linares L, García-Goez JF, Cervera C, Almela M, Sanclemente G, Cofán F et al. Early bacteremia after solid organ transplantation. Transplant Proc. 2009; 41 (6): 2262-2264.




2020     |     www.medigraphic.com